| Dr Wiphada Patricia Bandettini, MD | |
|
National Institutes Of Health Bldg 10, 10 Center Dr, Rm B1d-416, Bethesda, MD 20892-0001 | |
| (301) 896-4007 | |
| (301) 896-7521 |
| Full Name | Dr Wiphada Patricia Bandettini |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | National Institutes Of Health Bldg 10, 10 Center Dr, Bethesda, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013192582 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | D0057808 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Wiphada Patricia Bandettini, MD National Institutes Of Health Bldg 10, 10 Center Dr, Rm B1d-416, Bethesda, MD 20892-0001 Ph: (301) 896-4007 | Dr Wiphada Patricia Bandettini, MD National Institutes Of Health Bldg 10, 10 Center Dr, Rm B1d-416, Bethesda, MD 20892-0001 Ph: (301) 896-4007 |
News Archive
Young women diagnosed with breast cancer are uniquely impacted by issues often not faced by older women. Breast cancer is often detected at later stages, increasing diagnoses of more advanced cancers. The impact of cancer treatment on fertility, body image, financial challenges, and slightly higher mortality rates are significant concerns for this population.
Contego Medical, the first and only provider of the Integrated Embolic Protection filter platform for angioplasty balloon and stent delivery catheters, announces the completion of a $5.6 million Series B financing round led by Hatteras Venture Partners, an early stage venture firm with a focus on medical devices, biopharmaceuticals, diagnostics and related opportunities in human medicine.
BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy (DMD). The Phase 1 clinical trial was a single-center, double-blind, placebo-controlled, single-dose escalation study followed by a multiple-dose escalation study in healthy volunteers.
iCell Gene Therapeutics today (Aug. 11) announced that the Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL).
A Delaware County physician says health care is too important of an issue in the upcoming presidential election, and that the candidates should have a forum to talk about their vision for the future of health care.
› Verified 1 days ago
Ardalan Enkeshafi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6410 Rockledge Dr Ste 304, Bethesda, MD 20817 Phone: 443-602-6207 | |
Dr. Tara Palmore, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10 Center Dr, Msc 1888, Bethesda, MD 20892 Phone: 301-496-4000 | |
Dr. Cornelia Diana Cudrici, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10 Center Drive Bld 10 Rm 6n216a, Bethesda, MD 20892 Phone: 301-443-5519 | |
Shanthi Murgesh Nadar, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 8600 Old Georgetown Road, Bethesda, MD 20814 Phone: 301-896-3100 | |
Dr. Nicole Jeanine Gormley, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 10 Center Dr, Bldg 10, Rm 2c145, Bethesda, MD 20892 Phone: 301-496-9320 | |
Dr. Harshkumar Patel, MBBS Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 10 Center Dr, Bethesda, MD 20892 Phone: 301-496-9320 Fax: 301-402-1213 | |
Dr. Tung N Dao, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6410 Rockledge Dr, Ste 200, Bethesda, MD 20817 Phone: 301-897-5301 Fax: 301-564-4289 |